Roche receives FDA clearance on its digital pathology solution for diagnostic use
TUCSON, Ariz., June 18, 2024 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its whole-slide imaging system, the Roche Digital Pathology Dx (VENTANA DP 200), has received 510(k) clearance from the United States Food and Drug Administration (FDA). The system is intended to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.
Related news for (RHHBY)
- Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness
- Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
- 24/7 Market News- Sangamo Therapeutics Entered Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech
- Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
- New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions